Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−244.2720 USD
−32.34 M USD
0.00 USD
1.18 M
About NexImmune, Inc.
Sector
CEO
Craig R. Jalbert
Headquarters
Gaithersburg
Website
Founded
2011
FIGI
BBG00YZ6GG28
NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NEXI is 0.3500 USD — it has increased by 44.11% in the past 24 hours. Watch NexImmune, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange NexImmune, Inc. stocks are traded under the ticker NEXI.
NEXI stock has risen by 29.60% compared to the previous week, the month change is a 69.16% rise, over the last year NexImmune, Inc. has showed a −82.84% decrease.
NEXI reached its all-time high on Feb 12, 2021 with the price of 17,500.0000 USD, and its all-time low was 0.2000 USD and was reached on Oct 1, 2024. View more price dynamics on NEXI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NEXI stock is 52.37% volatile and has beta coefficient of 0.96. Track NexImmune, Inc. stock price on the chart and check out the list of the most volatile stocks — is NexImmune, Inc. there?
Today NexImmune, Inc. has the market capitalization of 488.13 K, it has decreased by −4.00% over the last week.
Yes, you can track NexImmune, Inc. financials in yearly and quarterly reports right on TradingView.
NexImmune, Inc. is going to release the next earnings report on Nov 25, 2024. Keep track of upcoming events with our Earnings Calendar.
NEXI net income for the last quarter is −2.33 M USD, while the quarter before that showed −3.08 M USD of net income which accounts for 24.39% change. Track more NexImmune, Inc. financial stats to get the full picture.
No, NEXI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 6.00 employees. See our rating of the largest employees — is NexImmune, Inc. on this list?
Like other stocks, NEXI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NexImmune, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NexImmune, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NexImmune, Inc. stock shows the sell signal. See more of NexImmune, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.